XIa因子(FXIa)是一种凝血酶,参与凝血酶生成的扩增。越来越多的证据表明,直接抑制FXIa可以阻止病理性血栓形成,同时保持正常止血。临床前研究使用多种降低FXIa活性的方法,包括FXIa的直接抑制剂,已证明在不增加出血的情况下具有良好的抗血栓形成作用。在此潜力的基础上,我们着力于确定FXIa的有效抑制剂,重点是发现一种可在医院环境中使用的急性抗血栓形成剂。本文中,我们描述了一种有效的FXIa临床候选物55(FXIa K i= 0.7 nM),在血栓形成模型中具有出色的临床前功效,并且水溶性适合静脉内给药。BMS-962212是FXIa的可逆,直接和高选择性小分子抑制剂。
Electroreduction of aromatic imines in the presence of electrophiles gave the corresponding inter- and intramolecular coupling products when the reaction was carried out with the use of chlorotrimethylsilane (CTMS) as the trapping agent of an anion intermediate.
An efficient methodology for the preparation of β-aminoacidderivatives () by CC bond formation from Schiff bases () and vinyloxyborane () and their utilization in the synthesis of the pyrimidine moiety () of bleomycin are described.
This newly developed single-flask, solvent-free process accomplishes sequential C−N and C−Cbondformations. It leads to (β-cyano)anilines by use of aryl triflates, Schiff bases, and CH3CN as a reagent. Key features of this neat method include a domino process, ambient temperature, short reaction time, and alignment with sustainability principles.